SET OF DRUGS FOR CONDUCTING A COURSE OF TERTIARY PREVENTION OF ONCOLOGICAL DISEASES FOR IMMUNOMODULATORY EFFECTS IN COMBINATION THERAPY AND A METHOD FOR TERTIARY PREVENTION OF ONCOLOGICAL DISEASES USING COMBINATION THERAPY USING A SET OF DRUGS FOR IMMUNOMODULATING EFFECTS Russian patent published in 2023 - IPC A61N5/10 A61K38/19 A61K38/14 A61K38/21 A61P35/00 

FIELD: medicine.

SUBSTANCE: invention relates to oncology, and is intended for tertiary prevention of oncological diseases, and specifically relates to a method of using maintenance immunotherapy after the end of the main stage of antitumor therapy. The invention can be used for tertiary prevention of oncological diseases in patients with a homo- or heterozygous TNF308 mutation variant. The set according to the invention includes Refnot preparation containing human tumor necrosis factor alpha and thymosin-alpha1-acetylated polypeptide, and Ingaron containing interferon gamma for their subcutaneous administration in equal therapeutic doses of 500,000 units. The method according to the invention includes surgical treatment of patients and chemotherapy or surgical treatment and hormone therapy, after which a course of treatment is carried out in the form of six courses of prophylactic treatment by sequential administration of a combination of drugs including Refnot containing human tumor necrosis factor alpha and thymosin-alpha1-acetylated polypeptide, and interferon gamma Ingaron. Refnot is administered subcutaneously at a dose of 500,000 units every other day for a 20-day course, and Ingaron is also administered subcutaneously at a dose of 500,000 units every other day for a 20-day course, and the first injection of Ingaron is carried out the next day after the administration of Refnot, then a break lasting for 10 days is required. After 45 days, computed tomography is performed to determine the presence or absence of signs of recurrence of the disease.

EFFECT: use of the inventions makes it possible to reduce the risk of recurrence and progression and improve the rates of relapse-free survival of patients with malignant diseases.

3 cl, 6 ex